Author

L. S. Crump

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

J. K. Richer· 2 shared G. L. Wyatt· 1 shared H. T. Lind· 1 shared K. I. O'Neill· 1 shared L.-W. Kuo· 1 shared M. C. Caino· 1 shared M. M. Williams· 1 shared N. G. Hammond· 1 shared

Activity by Year

2020-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. K. Richer

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

NPC1 confers metabolic flexibility in Triple Negative Breast Cancer

K. I. O'Neill, L.-W. Kuo, M. M. Williams, H. T. Lind, L. S. Crump, N. G. Hammond, N. S. Spoelstra, M. C. Caino, J. K. Richer

This study identifies NPC1 as a key driver of metabolic flexibility and aggressiveness in TNBC, showing its role in cholesterol homeostasis and therapeutic vulnerability.

bioRxiv · May 5, 2022Cancer Biology

Hormonal regulation of Semaphorin 7a in ER+ breast cancer drives therapeutic resistance

L. S. Crump, G. L. Wyatt, T. R. Rutherford, J. K. Richer, W. W. Porter, T. R. Lyons

This study identifies SEMA7A as a driver of therapeutic resistance in ER+ breast cancer and suggests targeting survival signaling pathways as a potential treatment strategy.

bioRxiv · Oct 5, 2020Cancer Biology